Live Breaking News & Updates on Bellerophon Therapeutics Inc|Page 17

Stay updated with breaking news from Bellerophon therapeutics inc. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

HC Wainwright Cuts Bellerophon Therapeutics (NASDAQ:BLPH) Price Target to $2.00

Bellerophon Therapeutics (NASDAQ:BLPH – Get Rating) had its price target reduced by HC Wainwright from $30.00 to $2.00 in a report issued on Tuesday, The Fly reports. HC Wainwright also issued estimates for Bellerophon Therapeutics’ Q4 2023 earnings at ($0.45) EPS, FY2023 earnings at ($1.11) EPS, FY2024 earnings at ($1.53) EPS, FY2025 earnings at ($0.78) […] ....

Bobae Kim , Renaissance Technologies , Geode Capital Management , Dimensional Fund Advisors , Bellerophon Therapeutics Inc , Securities Exchange Commission , Bellerophon Therapeutics , Get Rating , Life Science Opportu Puissance , Exchange Commission , Fund Advisors , Street Corp , Capital Management , Bellerophon Therapeutics Daily , Nasdaq Blph , Lower Price Target , Hc Wainwright ,

Bellerophon Therapeutics, Inc. (NASDAQ:BLPH) Major Shareholder Life Science Opportu Puissance Sells 134,421 Shares

Bellerophon Therapeutics, Inc. (NASDAQ:BLPH – Get Rating) major shareholder Life Science Opportu Puissance sold 134,421 shares of the firm’s stock in a transaction that occurred on Wednesday, June 7th. The shares were sold at an average price of $0.83, for a total value of $111,569.43. Following the completion of the sale, the insider now owns […] ....

Dimensional Fund Advisors , Renaissance Technologies , Bellerophon Therapeutics Company Profile , Bellerophon Therapeutics Inc , Geode Capital Management , Bellerophon Therapeutics , Get Rating , Life Science Opportu Puissance , Science Opportu Puissance , Brookline Capital Management , Fund Advisors , Street Corp , Capital Management , Bellerophon Therapeutics Daily , Nasdaq Blph , Insider Trading , Nsider Trades ,

Bellerophon Therapeutics (NASDAQ:BLPH) Cut to "Hold" at Brookline Capital Management

Brookline Capital Management cut shares of Bellerophon Therapeutics (NASDAQ:BLPH – Get Rating) from a buy rating to a hold rating in a report published on Monday morning, PriceTargets.com reports. Other equities analysts have also issued reports about the stock. StockNews.com upgraded shares of Bellerophon Therapeutics from a sell rating to a hold rating in a […] ....

Bobae Kim , Bellerophon Therapeutics Inc , Dimensional Fund Advisors , Bellerophon Therapeutics Company Profile , Renaissance Technologies , Securities Exchange Commission , Geode Capital Management , Brookline Capital Management , Bellerophon Therapeutics , Get Rating , Life Science Opportu Puissance , Exchange Commission , Fund Advisors , Street Corp , Capital Management , Bellerophon Therapeutics Daily , Nasdaq Blph ,

Bellerophon Therapeutics, Inc. Announces Top-Line Data from Phase 3 REBUILD Clinical Trial of INOpulse® for Treatment of Fibrotic Interstitial Lung Disease

Bellerophon Therapeutics, Inc. announced top-line results from its pivotal Phase 3 REBUILD clinical trial evaluating the safety and efficacy of INOpulse® for the treatment of fibrotic Interstitial. | June 6, 2023 ....

Bellerophon Therapeutics Inc , Bellerophon Therapeutics , Interstitial Lung Disease , Overall Activity , Walk Distance , Respiratory Questionnaire , Clinical Worsening , Clinical Deterioration , Clinical Improvement , Nc Stock Exchange , Press Release , Ibrotic Blph Us0787713009 ,

Bellerophon Therapeutics: Phase 3 REBUILD Trial Fails To Meet Primary Endpoint

Bellerophon Therapeutics, Inc. (BLPH) reported top-line results from Phase 3 REBUILD trial evaluating the safety and efficacy of INOpulse for the treatment of fibrotic Interstitial Lung Disease. ....

Peter Fernandes , Bellerophon Therapeutics Inc , More Such Health News , Bellerophon Therapeutics , Interstitial Lung ,